Dutasteride/tamsulosin, sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH).[3] It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.[2]
| Combination of | |
|---|---|
| Dutasteride | 5α-Reductase inhibitor |
| Tamsulosin | Alpha-1 blocker |
| Clinical data | |
| Trade names | Jalyn |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010.[4] In June 2011, the FDA approved a label change to warn of "Increased Risk of High-grade Prostate Cancer" from Jalyn.[5]
References
edit- ^ https://www.tga.gov.au/resources/prescription-medicines-registrations/dutalosin-ksj-pharmatech
- ^ a b "Jalyn - dutasteride and tamsulosin hydrochloride capsule". DailyMed. U.S. National Library of Medicine. Retrieved 28 December 2020.
- ^ Keating GM (May 2012). "Dutasteride/tamsulosin: in benign prostatic hyperplasia". Drugs & Aging. 29 (5): 405–19. doi:10.2165/11208920-000000000-00000. PMID 22550968. S2CID 209142875.
- ^ "Approval Package for: Dutasteride 0.5 mg/Tamsulosin hydrochloride 0.4 mg" (PDF). Center for Drug Evaluation and Research. Food and Drug Administration. 14 June 2010.
- ^ "Detailed View: Safety Labeling Changes: Jalyn (dutasteride and tamsulosin) capsules". Center for Drug Evaluation and Research. U.S. Food and Drug Administration. June 2011. Archived from the original on 6 January 2012.
